Inovum Hct

Olmesartan medoxomil, amlodipine and hydrochlorothiazide, the active ingredients in Inovum HCT, are antihypertensive agents presented as a tablet for oral use. They work together to lower elevated blood pressure in adult patients with hypertension. The combination targets multiple pathways involved in vascular tone and fluid balance, providing a comprehensive approach to blood pressure control.

GNH USA supplies Inovum HCT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union manufacturing standards and is distributed to a global network of healthcare providers, ensuring consistent quality and availability.

Inovum HCT is used to manage hypertension by acting on the renin‑angiotensin system, calcium channels, and renal fluid excretion. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Secondary hypertension: assists in controlling blood pressure when caused by identifiable underlying conditions. - Hypertension with renal involvement: provides effective pressure reduction while promoting diuresis. - Isolated systolic hypertension: improves arterial compliance and lowers systolic pressure. - Hypertension in elderly patients: offers once‑daily dosing convenience and balanced blood pressure control.

Inovum HCT may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: light‑headed feeling, often occurring when standing quickly. - Headache: mild to moderate pain in the head region. - Peripheral edema: swelling of the ankles or lower legs. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Electrolyte disturbances: abnormal sodium or potassium levels that may affect heart rhythm.

When prescribing Inovum HCT, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check BP regularly to assess therapeutic response. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor sodium and potassium levels, especially in patients on diuretics. - Concomitant drug review: avoid use with potassium‑sparing diuretics or strong CYP3A4 inhibitors. - Pregnancy and lactation: use only if benefits outweigh potential risks, after professional evaluation. - Store at room temperature: keep tablets in original container, protect from moisture and light.

Inovum HCT can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine concentrations. - Other antihypertensives (e.g., beta‑blockers): additive blood pressure lowering, risk of hypotension. - Antidiabetic agents: diuretic component may affect glucose control.